About 84.8% of all AML patients are characterized by seven fusion genes: KMT2A::MLLT3, KMT2A::MLLT10, KMT2A-PTD, KMT2A::ELL, KMT2A::AFDN, KMT2A::MLLT1, and KMT2A::MLLT11. This evidence concerns the gene MLLT10 and acute myeloid leukemia.